Human acute leukemia cells injected in NOD/LtSz‐scid/IL‐2Rγ null mice generate a faster and more efficient disease compared to other NOD/scid‐related strains

Transplantation of human acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) primary cells and cell lines in different strains of immunodeficient mice has led to preclinical models extensively used to investigate acute leukemia stem cells, biology and drug sensitivity. We studied the engraftment kinetics of AML and ALL cell lines and primary cells in 3 strains of NOD.CB17‐Prkdcscid (NOD/scid, NS)‐related mice (NOD.Cg‐PrkdcscidB2mtm1Unc/J, abbreviated NOD/scid/β2 null, NSB; and NOD.Cg‐PrkdcscidIl2rgtm1Wjll/SzJ, abbreviated NOD/scid/IL‐2Rγ null, NSG). The engraftment of human malignant cells was investigated by means of clinicopathological criteria, flow cytometry, PCR and immunohistochemistry. In NSG mice, we observed a significantly faster development of leukemia‐related symptoms and a higher percentage of leukemia cells in the blood, in the marrow and in the spleen. The leukemia‐related angiogenic switch (measured as the number of circulating endothelial cells and progenitors) was faster in NSG compared to NS and NSB mice. These models will be instrumental to studies on leukemia‐initiating stem cells, leukemia biology, preclinical treatment studies, and to obtain patient‐specific preclinical models to design and investigate patient‐tailored therapies. © 2008 Wiley‐Liss, Inc.

[1]  E. Voest,et al.  Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  中村 陽一.  Engraftment of NOD/SCID/γc[null] mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia , 2005 .

[3]  H. Ben‐Hur,et al.  β2 Microglobulin-deficient (B2mnull) NOD/SCID mice are excellent recipients for studying human stem cell function , 2000 .

[4]  Hong Zhang,et al.  Circulating endothelial progenitor cells in multiple myeloma: implications and significance. , 2005, Blood.

[5]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[6]  M. Rocchi,et al.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). , 2000, The American journal of pathology.

[7]  J. Kersey,et al.  Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects , 1998, Leukemia.

[8]  L. Ailles,et al.  Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. , 1999, Blood.

[9]  Mamoru Ito,et al.  Humanized NOD/SCID/IL2Rγnull Mice Transplanted with Hematopoietic Stem Cells under Nonmyeloablative Conditions Show Prolonged Life Spans and Allow Detailed Analysis of Human Immunodeficiency Virus Type 1 Pathogenesis , 2007, Journal of Virology.

[10]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[11]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[12]  G. Pruneri,et al.  The thin red line: angiogenesis in normal and malignant hematopoiesis. , 2000, Experimental hematology.

[13]  S. Kojima,et al.  Engraftment of NOD/SCID/γcnull mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia , 2005, British journal of haematology.

[14]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[15]  J. Nolta,et al.  Immune-deficient mouse models for analysis of human stem cells. , 2003, BioTechniques.

[16]  H. Ben‐Hur,et al.  beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function. , 2000, Blood.

[17]  河野 徳明.  Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/β2-microglobulin[null] mice , 2006 .

[18]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[19]  S. Yamasaki,et al.  Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/β2-microglobulinnull mice , 2005, Leukemia.

[20]  C. Kalberer,et al.  Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice , 2005, Leukemia.

[21]  P. Smolewski,et al.  Circulating endothelial cells in patients with acute myeloid leukemia , 2005, European journal of haematology.

[22]  C. Eaves,et al.  Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors , 2003, Leukemia.

[23]  G Pruneri,et al.  Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. , 2000, Cancer research.

[24]  J. Dick,et al.  Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice , 1999, Bone Marrow Transplantation.

[25]  Dale L. Greiner,et al.  Humanized mice in translational biomedical research , 2007, Nature Reviews Immunology.

[26]  Mamoru Ito,et al.  NOD / SCID / cnull mouse : an excellent recipient mouse model for engraftment of human cells , 2002 .

[27]  G. Pruneri,et al.  Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma , 2000, Leukemia.

[28]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[29]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[30]  N. Rooijen,et al.  Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes , 1997, Leukemia.

[31]  P. Smolewski,et al.  Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients , 2008, Annals of Hematology.

[32]  M. Westby,et al.  The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. , 1996, Blood.

[33]  Ø. Bruserud,et al.  Animal models of acute myelogenous leukaemia – development, application and future perspectives , 2005, Leukemia.

[34]  G. Pruneri,et al.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.

[35]  Robert S. Kerbel,et al.  The multifaceted circulating endothelial cell in cancer: towards marker and target identification , 2006, Nature Reviews Cancer.

[36]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[37]  E. Fuchs,et al.  Socializing with the Neighbors Stem Cells and Their Niche , 2004, Cell.

[38]  A. Nagler,et al.  Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. , 2005, Blood.

[39]  A. Doria,et al.  Multilineage engraftment of refrozen cord blood hematopoietic progenitors in NOD/SCID mice. , 2006, Haematologica.